Immunoassay Detects Syphilis and Assists Treatment Monitoring
By LabMedica International staff writers Posted on 29 Apr 2014 |
A new syphilis immunoassay assay enables detection of total antibodies to Treponema pallidum subspecies pallidum (detection of IgG & IgM antibodies against TpN15, TpN17 & TpN47).
Launched by Roche (Basel, Switzerland) and dubbed the Elecsys Syphilis assay, it complements the Mediace Rapid Plasma Reagin (RPR) and T. pallidum Latex Agglutination (TPLA) Roche assays. The Immunoassay is a diagnostic test to help detect patients infected with syphilis in routine clinical practice and to make sure donated blood is not infected with syphilis. The assay demonstrates 100% sensitivity and 99.88% specificity with perfect discrimination of results, eliminating the need for a grey zone, and delivering confidence in all stages of treponemal infection.
For over 25 years Roche has invested in the research and development of serology analyzers and assays so that, today, it offers one of the most comprehensive infectious diseases assay portfolios available on a single automated platform. With the new Elecsys Syphilis assay, the Roche Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease. Designed for the emerging needs of clinical laboratories for reliable and efficient detection of this disease, the test enhances Roche’s solutions portfolio in serology testing––the testing of antibodies formed as a response to an infection––and complements the most comprehensive offering for blood safety available on the market today.
Related Links:
Roche
Launched by Roche (Basel, Switzerland) and dubbed the Elecsys Syphilis assay, it complements the Mediace Rapid Plasma Reagin (RPR) and T. pallidum Latex Agglutination (TPLA) Roche assays. The Immunoassay is a diagnostic test to help detect patients infected with syphilis in routine clinical practice and to make sure donated blood is not infected with syphilis. The assay demonstrates 100% sensitivity and 99.88% specificity with perfect discrimination of results, eliminating the need for a grey zone, and delivering confidence in all stages of treponemal infection.
For over 25 years Roche has invested in the research and development of serology analyzers and assays so that, today, it offers one of the most comprehensive infectious diseases assay portfolios available on a single automated platform. With the new Elecsys Syphilis assay, the Roche Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease. Designed for the emerging needs of clinical laboratories for reliable and efficient detection of this disease, the test enhances Roche’s solutions portfolio in serology testing––the testing of antibodies formed as a response to an infection––and complements the most comprehensive offering for blood safety available on the market today.
Related Links:
Roche
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms